drugset
drugset / Trial / NCT04906096

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

NCT04906096 ↗

Phase 2 Recruiting 25 enrolled Lakshmi Nayak, MD Kazia Therapeutics Limited · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

Timeline

Start
2021-06-01
Primary completion
2026-12-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Paxalisib Small molecule — Oral

Indications

non-Hodgkin lymphoma primary central nervous system lymphoma